Fund cites strong launch of Insmed’s non-CF bronchiectasis therapy and $1B 2026 sales forecast as key drivers for the addition.
TimesSquare Capital’s U.S. Mid Cap Growth Strategy increased its position in Insmed Incorporated (INSM) during Q1 2026, citing the strong launch of Brinsupri, the first FDA-approved treatment for non-cystic fibrosis bronchiectasis. The stock closed at $106.62 on June 30, 2026, valuing the company at $23.11 billion.
Insmed’s shares rose 8.53% over the past year but dropped 6% in the quarter. While Arikayce sales lagged expectations, the fund expects Brinsupri to drive $1 billion in 2026 revenue, outweighing near-term underperformance.
The strategy focuses on biopharmaceutical firms addressing unmet medical needs with premium-priced therapies, aligning with Insmed’s rare disease pipeline.